Characterization of four new designer drugs, 5-chloro-NNEI, NNEI indazole analog, α-PHPP and α-POP, with 11 newly distributed designer drugs in illegal products.
Our continuous survey of illegal products in Japan revealed the new distribution of 15 designer drugs. We identified four synthetic cannabinoids, i.e., NNEI (1), 5-fluoro-NNEI (2), 5-chloro-NNEI (3) and NNEI indazole analog (4), and seven cathinone derivatives, i.e., MPHP (5), α-PHPP (6), α-POP (7), 3,4-dimethoxy-α-PVP (8), 4-fluoro-α-PVP (9), α-ethylaminopentiophenone (10) and N-ethyl-4-methylpentedrone (11). We also determined LY-2183240 (12) and its 2'-isomer (13), which were reported to inhibit endocannabinoid uptake, a methylphenidate analog, 3,4-dichloromethylphenidate (14), and an MDA analog, 5-APDB (15). No chemical and pharmaceutical data for compounds 3, 4, 6 and 7 had been reported, making this the first report on these compounds.
National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan. Electronic address: nuchiyama@nihs.go.jp.
Nahoko
N
Uchiyama
National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan.
Satoru
S
Matsuda
National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan.
Maiko
M
Kawamura
National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan.
Yoshihiko
Y
Shimokawa
National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan.
Ruri
R
Kikura-Hanajiri
Department of Molecular Behavioral Biology, Osaka Bioscience Institute, 6-2-4 Furuedai, Suita-City, Osaka 565-0874, Japan.
Kosuke
K
Aritake
Department of Molecular Behavioral Biology, Osaka Bioscience Institute, 6-2-4 Furuedai, Suita-City, Osaka 565-0874, Japan.
Yoshihiro
Y
Urade
National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan.
Yukihiro
Y
Goda
D000470:Alkaloids / Q000032:analysis / Q000737:chemistry; D002186:Cannabinoids / Q000032:analysis* / Q000737:chemistry; D000697:Central Nervous System Stimulants / Q000032:analysis* / Q000737:chemistry; D015198:Designer Drugs / Q000032:analysis* / Q000737:chemistry; D006573:Heterocyclic Compounds, 1-Ring / Q000032:analysis; D007564:Japan; D007880:Legislation, Drug; D008774:Methylphenidate / Q000031:analogs & derivatives / Q000032:analysis; D028321:Plant Preparations / Q000737:chemistry*; D011619:Psychotropic Drugs / Q000032:analysis* / Q000737:chemistry; D019966:Substance-Related Disorders / Q000517:prevention & control; D014508:Urea / Q000031:analogs & derivatives / Q000032:analysis
D000470:Alkaloids; D002186:Cannabinoids; D000697:Central Nervous System Stimulants; D015198:Designer Drugs; D006573:Heterocyclic Compounds, 1-Ring; C522826:LY2183240; D028321:Plant Preparations; D011619:Psychotropic Drugs; D008774:Methylphenidate; C023665:cathinone; D014508:Urea
3,4-Dichloromethylphenidate; 5-Chloro-NNEI; Cathinone derivative; NNEI indazole analog; Synthetic cannabinoid